GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Teva Pharmaceutical Industries Limited (TEVA) [hlAlert]

Rating:
Overweight
TEVA
up 43.29 %

Teva Pharmaceutical Industries (TEVA) upgraded to Overweight by HSBC Securities

Posted on: Monday,  Jun 30, 2008  8:25 AM ET by HSBC Securities

HSBC Securities rated Overweight Teva Pharmaceutical Industries Limited (NYSE: TEVA) on 06/30/2008, when the stock price was $45.50.
Since then, Teva Pharmaceutical Industries Limited has gained 43.30% as of 09/01/2015's recent price of $65.20.
If you would have followed this HSBC Securities's recommendation on TEVA, you would have gained 43.29% of your investment in 2619 days.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson?s disease and respiratory products. Teva?s active pharmaceutical ingredient business provides vertical integration to Teva?s own pharmaceutical production and sells to third party manufacturers. The Company?s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

HSBC has refined and refocused its Global Equities organisation, creating a lean and flexible business model built to meet the needs of global issuers and investors today and in the future. Acknowledging the changing demands of clients, we have also refined our research model, moving away from traditional maintenance to focus on long term, thematic research (a two-year-plus horizon) combined with short term (zero to three months), real-time, actionable ideas both for companies and sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/30/2008 8:25 AM Buy
None
45.50
as of 12/24/2008
1 Week down  -0.13 %
1 Month down  -1.26 %
3 Months up  6.46 %
1 YTD up  4.46 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/14/2008 10:50 AM Hold
None
47.46
10/31/2007 9:25 AM Buy
None
43.93 50.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy